Biogen (BIIB) Competitors $132.62 -0.57 (-0.42%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$132.87 +0.25 (+0.18%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAGE, SAVA, VRTX, BMY, and LLYShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Sage Therapeutics (SAGE), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Sage Therapeutics Cassava Sciences Vertex Pharmaceuticals Bristol Myers Squibb Eli Lilly and Company Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Do analysts prefer BIIB or AMGN? Biogen presently has a consensus target price of $188.48, indicating a potential upside of 42.12%. Amgen has a consensus target price of $307.82, indicating a potential upside of 3.21%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 Which has better earnings and valuation, BIIB or AMGN? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.01$1.63B$10.1313.09Amgen$33.42B4.80$4.09B$10.9627.21 Which has more volatility and risk, BIIB or AMGN? Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Does the media prefer BIIB or AMGN? In the previous week, Amgen had 45 more articles in the media than Biogen. MarketBeat recorded 59 mentions for Amgen and 14 mentions for Biogen. Amgen's average media sentiment score of 1.07 beat Biogen's score of 0.83 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 48 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Is BIIB or AMGN more profitable? Amgen has a net margin of 17.39% compared to Biogen's net margin of 15.07%. Amgen's return on equity of 176.11% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.07% 14.03% 8.32% Amgen 17.39%176.11%12.39% Do institutionals and insiders believe in BIIB or AMGN? 87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAmgen beats Biogen on 13 of the 17 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.47B$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio13.0921.5627.6120.24Price / Sales2.01278.93417.30118.22Price / Cash5.7542.7336.8958.10Price / Book1.167.518.035.67Net Income$1.63B-$55.14M$3.18B$249.21M7 Day Performance5.19%4.61%2.93%3.28%1 Month Performance1.74%4.72%3.75%5.55%1 Year Performance-41.23%5.92%35.20%21.09% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.9303 of 5 stars$132.63-0.4%$188.48+42.1%-41.0%$19.47B$9.68B13.097,605AMGNAmgen4.5225 of 5 stars$276.91-0.1%$307.82+11.2%-3.6%$148.90B$33.42B25.2728,000GILDGilead Sciences4.8432 of 5 stars$110.21-0.4%$110.55+0.3%+67.1%$137.09B$28.75B23.2017,600Positive NewsInsider TradeIONSIonis Pharmaceuticals4.6752 of 5 stars$39.59-0.5%$57.88+46.2%-5.7%$6.30B$705M-13.241,069News CoverageAnalyst UpgradeMRNAModerna4.3797 of 5 stars$27.55+1.4%$46.61+69.2%-73.7%$10.65B$3.24B-3.165,800Options VolumePRTAProthena3.0703 of 5 stars$6.14+1.0%$31.50+413.0%-67.8%$330.52M$135.16M-2.95130SAGESage Therapeutics3.2294 of 5 stars$9.08-0.8%$8.93-1.6%-13.4%$568.60M$47.40M-1.57690SAVACassava Sciences3.8651 of 5 stars$1.83+4.3%$54.50+2,886.3%-81.3%$88.17MN/A-1.2230VRTXVertex Pharmaceuticals4.7218 of 5 stars$444.74+0.8%$511.62+15.0%-3.3%$114.21B$11.02B-113.456,100Positive NewsBMYBristol Myers Squibb4.9456 of 5 stars$46.48+0.3%$58.00+24.8%+17.4%$94.59B$48.30B17.4134,300Positive NewsLLYEli Lilly and Company4.9885 of 5 stars$777.19+0.2%$1,011.61+30.2%-13.2%$736.57B$45.04B63.2447,000Trending News Related Companies and Tools Related Companies Amgen Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Sage Therapeutics Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
